

Genetron Health, Siemens Healthineers to help standardize cancer molecular testing in China

17 May 2021 | News

This partnership aims to promote large scale application of Genetron's S5 platform and lung cancer 8-gene IVD assay in Chinese hospitals



Genetron Holdings, based in China, a company that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, has announced a strategic partnership with German firm Siemens Healthineers.

This partnership aims to promote large scale application of Genetron's S5 platform and lung cancer 8-gene IVD assay in Chinese hospitals, in order to provide non-small cell lung cancer (NSCLC) patients with efficient and accurate personalized diagnosis and treatment guidance.

The companies also plan to work together to standardize cancer molecular testing in hospitals.

"Genetron Health focuses on the innovation, clinical transformation and commercialization of cancer genomics technologies. Both our lab developed test (LDT) and in vitro diagnostic (IVD) products' business models have been progressing well," said Sizhen Wang, Co-founder and CEO of Genetron Health. "We are pleased to collaborate with Siemens Healthineers for our S5 instrument and lung 8 IVD assay, which helps diagnose and treat cancer patients. We also expect this partnership to help standardize cancer molecular testing in China, and reach more patients in need," Wang said.